Journal article · 2021 · Open access
Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM): A Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Reported Data from the BE RADIANT Phase 3b Trial
Advances in Therapy, 38(10), 5253–5269 · Published 2 September 2021 · DOI 10.1007/s12325-021-01836-1
In brief
“Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM): A Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Reported Data from the BE RADIANT Phase 3b Trial” is a 2021 journal article by Alice Bendix Gottlieb and 7 co-authors, published in Advances in Therapy. OpenAlex counts 7 citations as of 22 November 2026. It is open access under a CC BY-NC licence: the full text is free to read at Advances in Therapy.
- Citations
- 7
- Most cited in
- 2022 (4)
- Field-weighted impact
- 0.50
- References
- 16
- Authors
- 8
Abstract
INTRODUCTION: This analysis assessed the psychometric properties of the Psoriasis Symptoms and Impacts Measure (P-SIM), a novel patient-reported outcome (PRO) tool designed to capture patient experiences of the signs, symptoms and impacts of psoriasis. METHODS: Blinded data from the BE RADIANT phase 3b trial of bimekizumab were analysed. In BE RADIANT, patients were randomised 1:1 to bimekizumab 320 mg every 4 weeks (Q4W) or secukinumab 300 mg (weekly until Week 4, then Q4W). Three items (itching, skin pain and scaling) of the P-SIM were electronically assessed throughout the trial and were scored from 0 to 10 (none to very severe signs/symptoms/impacts). Test-retest reliability was determined using intraclass correlations. Convergent validity was assessed between P-SIM and other relevant PRO and clinician-reported outcome (ClinRO) scores. Known-groups validity was assessed by comparing mean P-SIM item scores between patient subgroups based on the Psoriasis Area and Severity Index (PASI)/Investigator's Global Assessment (IGA) scores. Responsiveness was assessed via correlations between changes from baseline in P-SIM item scores and other relevant PRO and ClinRO scores. Anchor-based responder analyses and empirical cumulative distribution function (eCDF) curves determined responder thresholds. RESULTS: The three P-SIM items yielded high intraclass coefficients (> 0.70). By Week 48, the three P-SIM items had moderate (> 0.30 and ≤ 0.50) to strong (> 0.50) correlations with other PROs and weaker correlations with ClinROs, demonstrating good convergent validity. For almost all known-group comparisons, statistically significant between-subgroup score differences were seen across all three P-SIM items. Changes from baseline in the P-SIM and other relevant outcomes were above the acceptable threshold of ≤ 0.30, demonstrating sensitivity to change. Anchor-based analyses determined a ≥ four-point reduction from baseline to indicate marked clinically meaningful improvement for the P-SIM. CONCLUSION: These results support the validity, reliability and sensitivity to change of the P-SIM in assessing key symptoms (itching, skin pain and scaling) in patients with moderate to severe plaque psoriasis. TRIAL REGISTRATION: NCT03536884.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Gottlieb, A. B., Warren, R. B., Augustin, M., Garcia, L., Cioffi, C., Peterson, L., Pelligra, C. G., & Ciaravino, V. (2021). Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM): A Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Reported Data from the BE RADIANT Phase 3b Trial. Advances in Therapy, 38(10), 5253–5269. https://doi.org/10.1007/s12325-021-01836-1
MLA 9
Gottlieb, Alice Bendix, et al. “Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM): A Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Reported Data from the BE RADIANT Phase 3b Trial.” Advances in Therapy, vol. 38, no. 10, 2021, pp. 5253–5269. https://doi.org/10.1007/s12325-021-01836-1.
Chicago
Gottlieb, Alice Bendix, Richard Bruce Warren, Matthias Augustin, Llenalia Garcia, Christopher Cioffi, Luke Peterson, Christopher G. Pelligra, and Valérie Ciaravino. 2021. “Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM): A Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Reported Data from the BE RADIANT Phase 3b Trial.” Advances in Therapy 38 (10): 5253–5269. https://doi.org/10.1007/s12325-021-01836-1.
Harvard
Gottlieb, A. B. et al. (2021) ‘Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM): A Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Reported Data from the BE RADIANT Phase 3b Trial’, Advances in Therapy, 38(10), pp. 5253–5269. doi:10.1007/s12325-021-01836-1.
IEEE
A. B. Gottlieb et al., “Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM): A Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Reported Data from the BE RADIANT Phase 3b Trial,” Advances in Therapy, vol. 38, no. 10, pp. 5253–5269, 2021, doi: 10.1007/s12325-021-01836-1.
BibTeX
@article{gottlieb2021psychometric,
title = {{Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM): A Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Reported Data from the BE RADIANT Phase 3b Trial}},
author = {Gottlieb, Alice Bendix and Warren, Richard Bruce and Augustin, Matthias and Garcia, Llenalia and Cioffi, Christopher and Peterson, Luke and Pelligra, Christopher G. and Ciaravino, Valérie},
journal = {Advances in Therapy},
year = {2021},
volume = {38},
number = {10},
pages = {5253--5269},
doi = {10.1007/s12325-021-01836-1},
url = {https://doi.org/10.1007/s12325-021-01836-1}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2022 | 4 | |
| 2023 | 1 | |
| 2024 | 1 | |
| 2026 | 1 |
Its field-weighted citation impact is 0.50: it has been cited 0.50 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- plaque psoriasis
- patient-reported outcomes
- psychometric validation
- bimekizumab
- secukinumab
- pruritus
- skin pain
- scaling
Work with this paper
Most-cited papers in Immunology and Microbiology
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Ulrich K. Laemmli · Nature · 1970 · 249,784 citations
- Atherosclerosis — An Inflammatory DiseaseRussell Ross · New England Journal of Medicine · 1999 · 21,957 citations
- Continuous cultures of fused cells secreting antibody of predefined specificityGeorges Köhler, César Milstein · Nature · 1975 · 17,450 citations
- Inflammation and cancerLisa M. Coussens, Zena Werb · Nature · 2002 · 15,462 citations
- Dendritic cells and the control of immunityJacques Banchereau, Ralph M. Steinman · Nature · 1998 · 14,526 citations
Questions about this paper
How do I cite this paper in APA style?
Gottlieb, A. B., Warren, R. B., Augustin, M., Garcia, L., Cioffi, C., Peterson, L., Pelligra, C. G., & Ciaravino, V. (2021). Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM): A Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Reported Data from the BE RADIANT Phase 3b Trial. Advances in Therapy, 38(10), 5253–5269. https://doi.org/10.1007/s12325-021-01836-1
How many times has this paper been cited?
7 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Advances in Therapy: sign in and open the PDF from this page.
Who wrote this paper?
Alice Bendix Gottlieb, Richard Bruce Warren, Matthias Augustin, Llenalia Garcia, Christopher Cioffi, Luke Peterson, Christopher G. Pelligra, Valérie Ciaravino.
What is the DOI of this paper?
10.1007/s12325-021-01836-1, permanently at https://doi.org/10.1007/s12325-021-01836-1. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.